No price history available.
Key financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | MYRm | 201 | 244 | 311 | 346 | 346 | N/A | N/A | N/A |
| Operating profit | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | MYRm | 20 | 41 | 39 | 41 | 4 | N/A | N/A | N/A |
| EPS reported | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
TMC Life Sciences Berhad operates as an investment holding entity, specializing in the provision of healthcare services throughout Malaysia. Its primary asset is Thomson Hospital Kota Damansara (THKD), a substantial 559-bed medical facility located in Selangor. THKD delivers a comprehensive spectrum of medical specialties, including orthopedics, ear, nose, and throat (ENT) care, head and neck laser procedures, dedicated services for women and children, fertility treatments, dietetic guidance, and emergency care. The company's fertility centers offer advanced reproductive technologies such as time-lapse imaging, preimplantation genetic testing, and fertility genecode analysis, alongside expert consultancy services. Beyond its main hospital operations, TMC Life Sciences manages a network of women's clinics and fertility centers, provides laboratory and embryology services, traditional and complementary medicine, and operates pharmacy outlets. Its activities further extend to developing and marketing healthcare programs, offering multi-disciplinary tertiary care support, engaging in research and development initiatives, and undertaking property investments. Established in 1994 and based in Petaling Jaya, Malaysia, the company is a subsidiary of Sasteria (M) Pte. Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
TMC Life Sciences Berhad operates as an investment holding entity, specializing in the provision of healthcare services throughout Malaysia. Its primary asset is Thomson Hospital Kota Damansara (THKD), a substantial 559-bed medical facility located in Selangor. THKD delivers a comprehensive spectrum of medical specialties, including orthopedics, ear, nose, and throat (ENT) care, head and neck laser procedures, dedicated services for women and children, fertility treatments, dietetic guidance, and emergency care. The company's fertility centers offer advanced reproductive technologies such as time-lapse imaging, preimplantation genetic testing, and fertility genecode analysis, alongside expert consultancy services. Beyond its main hospital operations, TMC Life Sciences manages a network of women's clinics and fertility centers, provides laboratory and embryology services, traditional and complementary medicine, and operates pharmacy outlets. Its activities further extend to developing and marketing healthcare programs, offering multi-disciplinary tertiary care support, engaging in research and development initiatives, and undertaking property investments. Established in 1994 and based in Petaling Jaya, Malaysia, the company is a subsidiary of Sasteria (M) Pte. Ltd.